Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on December 19, 2025. The Company is an emerging growth company with its principal executive offices in San Antonio, Texas. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate governance event rather than financial performance.
Material Changes and Corporate Events
On December 19, 2025, the Company convened a special meeting of stockholders but determined to adjourn the meeting without conducting any business. The adjournment occurred because the Company did not have a sufficient number of shares present in person or represented by proxy to constitute a quorum.
- Reconvened Meeting Date: Monday, January 19, 2026, at 8:00 a.m. Central Time.
- Record Date: November 4, 2025 (remains unchanged).
- Proposals: No changes have been made to the proposals to be voted on.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or new risk factors. The primary contingency noted is the requirement for stockholders to vote to achieve a quorum at the reconvened meeting. Stockholders who have already voted do not need to take further action unless they wish to change their vote.
Key Facts for Investor Verification
- Verify the specific proposals listed in the definitive proxy statement on Schedule 14A filed on November 7, 2025.
- Confirm the voting instructions and deadlines for the reconvened meeting on January 19, 2026.
- Monitor whether a quorum is achieved at the January 19, 2026 meeting to avoid further adjournments.